Tallac therapeutics announces first patient dosed with tac-001, a first-in-class toll-like receptor 9 agonist antibody conjugate, in a phase 1/2 study for patients with advanced solid tumors

Burlingame, calif.--(business wire)--tallac therapeutics, inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with tac-001 in a phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. tac-001 is the company's lead clinical candidate from its novel toll-like receptor agonist antibody conjugate (traac) platform and the first to enter the clinic. “the ini
ALXO Ratings Summary
ALXO Quant Ranking